Medicare AdvantagePrior AuthLow impact
Vanrafia™ (atrasentan) tablets (Revised)
Humana·Nephrology, Family Medicine, Internal Medicine·Medicare Advantage
Effective date
Jun 25, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Vanrafia (atrasentan) tablets used to treat primary immunoglobulin A nephropathy (IgAN). Four specific criteria must be met including biopsy-confirmed diagnosis, specific protein levels, and failed ACE inhibitor/ARB therapy.
Action Required
By June 25, 2025: Billing team must ensure providers obtain prior authorization for all Vanrafia (atrasentan) prescriptions for Medicare Advantage patients. Update pharmacy prior auth protocols to verify biopsy-confirmed IgAN diagnosis, UPCR ≥1.5g/g, failed ACE inhibitor/ARB therapy, and high CKD progression risk. Claims will be denied without prior authorization.